Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)
A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring
Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Fujian
-
Fuzhou, Fujian, Chiny
- Fujian Provincial Hospital
-
Fuzhou, Fujian, Chiny
- First Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Chiny
- Hui'an County Hospital
-
Quanzhou, Fujian, Chiny
- Second Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Chiny
- Shishi City Hospital
-
Zhangzhou, Fujian, Chiny
- Zhangzhou Municipal Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.
Opis
Inclusion Criteria:
- Age 18 years or older
- Continuous intracranial pressure monitoring for at least 24 hours
- Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
- Written informed consent from the patient or a legal representative
Exclusion Criteria:
- Incomplete or unusable intracranial pressure recordings
- Loss to follow-up or unavailable outcome information
- Pre-existing severe neurological disease that would confound assessment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Neurocritical care cohort
Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark. |
Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Ramy czasowe: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval |
24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Ramy czasowe: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals |
48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
|
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Ramy czasowe: 24, 48 and 72 hours after intensive care admission
|
Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting. |
24, 48 and 72 hours after intensive care admission
|
|
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Ramy czasowe: 24, 48 and 72 hours after intensive care admission
|
Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance. |
24, 48 and 72 hours after intensive care admission
|
|
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Ramy czasowe: 24, 48 and 72 hours after intensive care admission
|
Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II |
24, 48 and 72 hours after intensive care admission
|
|
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Ramy czasowe: 24 hours after intensive care admission
|
Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none |
24 hours after intensive care admission
|
|
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Ramy czasowe: 24, 48 and 72 hours after intensive care admission
|
Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small |
24, 48 and 72 hours after intensive care admission
|
|
28-day all-cause mortality, as specified in the approved protocol
Ramy czasowe: 28 days after intensive care admission
|
28 days after intensive care admission
|
|
|
Length of intensive care stay
Ramy czasowe: From intensive care admission to intensive care unit discharge, up to 28 days
|
Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care |
From intensive care admission to intensive care unit discharge, up to 28 days
|
|
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Ramy czasowe: 6 months after intensive care admission
|
Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up |
6 months after intensive care admission
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Han Chen, MD, Fujian Provincial Hospital
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Zaburzenia naczyniowo-mózgowe
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Choroby naczyniowe
- Choroby układu krążenia
- Rany i urazy
- Procesy patologiczne
- Atrybuty choroby
- Krwotok
- Uraz czaszkowo-mózgowy
- Uraz, układ nerwowy
- Krwotoki śródczaszkowe
- Urazy mózgu
- Stany patologiczne, oznaki i objawy
- Urazy mózgu, traumatyczne
- Śmiertelna choroba
- Krwotok mózgowy
- Krwotok podpajęczynówkowy
- Nadciśnienie wewnątrzczaszkowe
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- FJPH-ICP-01
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .